Form 8-K ABBOTT LABORATORIES For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Abbott (ABT) Confirms FY22 EPS of at Least $4.70 Despite Recall
February 18, 2022 1:06 PM ESTAbbott (NYSE: ABT) Confirms FY22 EPS of at least $4.70 Despite Recall
From the company:
On February 17, 2022, Abbott initiated a proactive, voluntary recall of Similac-brand powder infant formulas manufactured in Sturgis, Michigan. The recall primarily involves product distributed in the U.S. and... More
